103 results about "IMMUNE SUPPRESSANTS" patented technology

Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.

The invention relates to cell stimulatory fusion proteins and DNA sequences, vectors comprising at least two agonists of TNF/TNFR super family, immunoglobulin super family, cytokine family proteins and optional antigen combination. Instructions for use of these proteins and DNA constructs as immune adjuvants and vaccines for treatment of various chronic diseases such as viral infection are also provided. Additionally, the use of these protein and DNA constructs as immune suppressant for treatment of various chronic diseases, such as autoimmunity and organ transplant rejection, is also illustrated.

Disclosed are synthetic nanocarrier methods, and related compositions, comprising administering B cell and/or MHC Class II-restricted epitopes of an antigen and immunosuppressants in order to reduce antigen-specific activation of innate immune cells.

Compositions and methods can be used for tolerizing the immune system. The compositions can be physiologically acceptable and can include any of a wide variety of allergens that are designed to be administered in escalating doses to, for example, an infant. The compositions can include other active ingredients (e.g., one or more of a steroid, vitamin, mineral, vasodilator, hormone, decongestant, anticholinergic agent, leukotriene inhibitor, immunomodulator, mast cell stabilizer, expectorant, immune suppressant, anti-histamine, or anti-inflammatory agent) and/or a carrier.

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

The invention relates to an indoleamine 2,3-dioxygenase inhibitor with a structure represented by the formula (I) and a preparation method and applications thereof. The indoleamine 2,3-dioxygenase (IDO) inhibitor is the derivative of (Z)-N'-hydroxyl-N-phenyl formamidine, has an extremely high activity on inhibiting IDO, can effectively inhibit the activity of IDO, and can be used to inhibit the immunity inhibition of patients. The inhibitor can be widely used to treat or prevent cancer/tumor, viral infection, depression, neurodegenerative diseases, wounds, age related cataract, organ-graft refection, and autoimmune disease, and can be advantageously to be used as a novel immune-suppressor.

The invention relates to compounds that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Provided herein are methods and compositions related to nucleic acids encoding ornithine transcarbamylase (OTC), such as nucleic acids comprising an OTC codon-optimized sequence, as well as related vectors, such as AAV vectors. Also, provided are methods for administering AAV vectors that comprise a sequence that encodes an enzyme associated with an urea cycle disorder and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.

The invention relates to modification sites capable of enabling human interleukin-2 to carry out targeted activation on Treg, human interleukin-2 subjected to site-directed mutation on the modification sites, and human interleukin-2 subjected to site-directed modification on the modification sites. The modified long-acting interleukin-2 can carry out targeted activation regulation on T cells in awide therapeutic window, slightly and evenly does not activate other effector cells, and performs a long-acting systematic immunorepressive effect. The invention further relates to application of thecategory of site-directed mutation or modification interleukin-2, and purposes of the site-directed mutation or modification interleukin-2 for treating various autoimmunity diseases as a stable and long-acting immunosuppressor.

Methods of prolonging survival of a transplanted organ, as well as methods of preventing or attenuating rejection of a transplanted organ are provided. These methods involve contacting the organ with an inhibitor of complement activity (e.g., a complement inhibitor that has a maximum molecular weight of 70 kDa and/or a half-life shorter than 10 days, such as a CR2-FH fusion protein or a single chain anti-C5 antibody), prior to transplantation The methods also include administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. A pretreatment with an alternative complement inhibitor was found to be effective in improving graft survival and decreasing ischemia-reperfusion injury in animal.

The invention provides a tetrahydroquinoline alkaloid Malaysiensin with immunosuppression activity and a production method and application of the tetrahydroquinoline alkaloid Malaysiensin with the immunosuppression activity. The compound is obtained by conducting SFM solid medium fermentation on Streptomyces sp.DSM 4137 and separating and purifying a fermentation product. The compound can significantly inhibit ConA-induced proliferation of T cells, an immunosuppression effect of the compound is equivalent to that of an immunosuppressor cyclosporin A which is clinically and widely used, and action mechanism studies show that Malaysiensin exerts the immunosuppression activity for a targeted NFAT signal path, is an efficient immunosuppressor, and can be used for producing immunosuppressive medicines for organ transplantation and autoimmune diseases.

The invention relates to the gene exploitation and application field of the biomedicine high-tech, in particular to an artificial antigen amino acid sequence which is provided with a plurality of epipositions and can be identified by blood serum of falciparum malaria sufferers and a polynucleotide sequence coded with the amino acid sequence. The invention also relates to a vaccine containing the amino acid sequence or the polynucleotide sequence. The invention further also relates to the application of the artificial antigen used for preparing the immunity preparation against the falciparum malaria parasite.

The present invention discloses conjugates, having a general formula (I), obtained by condensation of dihydroartemisinin and steroids, or isomers or pharmaceutically acceptable salts or prodrug molecules thereof. The 10-position hydroxyl group of artemisinin and the 3-position hydroxyl group of the steroid compounds are condensed and linked by an ether bond. The invention discloses a preparation method of the compounds, and an application of the compounds in the treatment of autoimmune diseases. The dihydroartemisinin and steroid conjugates of the present invention are novel immunosuppressants, and can be used alone or in combination with other drugs to treat the human autoimmune diseases. The conjugates have the advantages of high curative effect, small toxicity and very broad applicationprospect.

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbpl, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Water-soluble artemisinin derivatives, their preparation methods, the pharmaceutical compositions containing the same derivatives and the use thereof are disclosed. The artemisinin derivatives have following formula I. It has been proved by pharmacological tests that these compounds and compositions have evident immuno-suppressive activities, and may be used in the preparation of novel immuno-suppressants for treating the diseases caused by hyperfunction of human immunity (e.g. the auto-immune diseases such as lupus erythematosus, rheumatoid arthritis, multiple sclerosis and the like), and for inhibiting the graft rejection after cell or organ transplantation.

The invention discloses a Mn-based degradable MOF nano-reactor and a preparation method and application thereof, the nano-reactor comprises an inner core Mn-based MOF nano-particle, the surface of the inner core Mn-based MOF nano-particle is functionalized and grafted with a pH responsive shell copolymer PEG-CDM-PEI, and the Mn-based MOF nano-particle is loaded with a biological enzyme GOx and an IDO immunosuppressor. The pH/ROS dual-responsive MOF nanoreactor drug controlled release system co-loaded with an immune checkpoint IDO inhibitor 1-MT and GOx is prepared by utilizing the advantages of high loading capacity, enzyme reaction space limitation, ROS responsive degradability and the like of an MOF nanoreactor, and tumor hunger/oxidation/IDO immune combined therapy is regulated and controlled. The drug-controlled system can respond to a weakly acidic tumor microenvironment, induce size reduction/charge reversal, overcome in-vivo tumor permeation and cell barrier, and improve the delivery efficiency; in addition, the self-enhanced MOF degradation and drug release performance is achieved; moreover, the immune therapy mediated by the drug control system can effectively inhibit the immune tolerance, enhance the anti-tumor immune response of the body and inhibit the growth, metastasis and relapse of tumors.